EcoDrugPlus

Proteasome Subunit Beta Type-11-Like

Ensembl ID : ENSSTUG00000005520
Gene Symbol: LOC115159010
3 Cross references
159 Possible Orthologues:

Proteasome Subunit Beta Type-2-Like

Ensembl ID : ENSSTUG00000044237
Gene Symbol: LOC115173445
3 Cross references
213 Possible Orthologues:

Proteasome Subunit Beta Type-2-Like

Ensembl ID : ENSSTUG00000034970
Gene Symbol: LOC115175970
3 Cross references
214 Possible Orthologues:

Proteasome Subunit Beta Type-3

Ensembl ID : ENSSTUG00000019890
Gene Symbol: LOC115178397
3 Cross references
253 Possible Orthologues:

Proteasome Subunit Beta Type-3-Like

Ensembl ID : ENSSTUG00000002443
Gene Symbol: LOC115208672
3 Cross references
254 Possible Orthologues:

Proteasome Subunit Beta Type-4-Like

Ensembl ID : ENSSTUG00000020779
Gene Symbol: LOC115175861
3 Cross references
207 Possible Orthologues:

Proteasome Subunit Beta Type-5-Like

Ensembl ID : ENSSTUG00000009649
Gene Symbol: LOC115157330
3 Cross references
190 Possible Orthologues:

Proteasome Subunit Beta Type-5-Like

Ensembl ID : ENSSTUG00000012587
Gene Symbol: LOC115192410
3 Cross references
158 Possible Orthologues:

Proteasome Subunit Beta Type-5-Like

Ensembl ID : ENSSTUG00000005488
Gene Symbol: LOC115158491
3 Cross references
158 Possible Orthologues:

Proteasome Subunit Beta Type-6-Like

Ensembl ID : ENSSTUG00000024942
Gene Symbol: LOC115183248
3 Cross references
225 Possible Orthologues:

Proteasome Subunit Beta Type-7-Like

Ensembl ID : ENSSTUG00000035804
Gene Symbol: LOC115173569
3 Cross references
164 Possible Orthologues:

Proteasome Subunit Beta Type-7-Like

Ensembl ID : ENSSTUG00000031673
Gene Symbol: LOC115175893
3 Cross references
165 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).